RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by our mission to treat inflammatory and immunologic diseases. Our cutting-edge science is fully focused on …

RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with …

RAPT Therapeutics is focused on the development of therapies for patients with significant unmet needs in inflammatory and immunologic diseases. Utilizing our deep and proprietary expertise …

Our proprietary drug discovery and development engine has identified several immune drivers that have the ability to be “tuned down” to suppress an overactive immune response in …

Oct 27, 2025 · RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies October 27, 2025 Trial initiation in food allergy …

Apr 15, 2025 · RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients …

At RAPT Therapeutics, we believe in bringing our whole selves to work each day, which requires important work-life balance. We encourage all employees to rejuvenate by sharing …

Dec 23, 2024 · RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with significant …

Dec 31, 2023 · RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results March 07, 2024 Company maintains solid cash position of $158.9 million SOUTH SAN …

Sep 30, 2025 · RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights November 06, 2025 - Initiated prestIgE Phase 2b trial of ozureprubart in food allergy …